Application Note

Improved T Cell Expansion Using Closed, Automatic Stirred-Tank Bioreactors And CTS OpTmizer Pro SFM

T cells cancer cells

In addition to improving the lives of these patients, T Cell therapies possess the potential to address countless other disease states. As such, the T cell therapy market has recently flourished and is expected to grow to $20.3 billion by 2028. In this rapidly expanding field, automation, improved control, and preparation for effective scale-up are critical to the success of these therapies. This has led cell therapy manufacturers to lean heavily on the use of bioreactors for cell expansion, because of their closed and automated design as well as their ability to create an optimal cell environment.

Learn about what to considering when scaling up to larger bioreactors, along with a process that was developed for expanding T cells in a 3 L HyPerforma Glass Bioreactor using CTS OpTmizer Pro SFM.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online